Interv Akut Kardiol. 2014;13(2):77-85

Dual antiplatelet therapy in patients after surgical revascularization of myocardium

Andrej Myjavec, Miroslav Brtko

Kardiocentrum, Kardiochirugická klinika, LF UK Hradec Králové

Aortocoronary bypass graft surgery with the use of arterial and/or venous grafts is well-established method of cardiac revascularization.

While the long-term patency of arterial grafts is outstanding, venous grafts are burdened with quite a high rate of occlusions, potentially

posing a risk of myocardial infarction, necessity of revascularization and death to the patient. Acetylosalysic acid is indicated in

all patients with ischemic heart disease (in the absence of contraindications). Its early administration is important in order to prevent

venous graft occlusion as well as to affect morbidity and mortality in the patients after the surgical revascularization of myocardium.

Whether dual antiplatelet therapy by adding clopidogrel or ticagrelor or prasugrel to acetylosalysic acid may further improve outcomes

of these patients remains unresolved. The results of the clinical trials and current opinion are presented in this review article. The existing

knowledge on the new P2Y12 receptor antagonists (ticagrelor and prasugrel) is mentioned as well.

Keywords: aortocoronary bypass graft, dual antiplatelet therapy, novel P2Y12 receptor antagonists

Published: May 15, 2014  Show citation